Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.44), $0.06 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $143 million versus the consensus estimate of $134.84 million.

GUIDANCE:

Exact Sciences sees FY2019 revenue of $710-730 million, versus the consensus of $704.35 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.